These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6792664)

  • 1. [Cost effectiveness of pneumococcal vaccine (author's transl)].
    Levy E
    Rev Epidemiol Sante Publique; 1981; 29(2):133-53. PubMed ID: 6792664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of vaccination against pneumococcal pneumonia.
    Willems JS; Sanders CR; Riddiough MA; Bell JC
    N Engl J Med; 1980 Sep; 303(10):553-9. PubMed ID: 6772950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
    Mangtani P; Roberts JA; Hall AJ; Cutts FT
    Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
    Ortqvist A; Jönsson B; Baltussen R; Ament A
    Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs.
    Weycker D; Richardson E; Oster G
    Am J Manag Care; 2000 Jul; 6(10 Suppl):S526-35. PubMed ID: 11183904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The cost-effectiveness of pneumococcal vaccination in Catalonia].
    Plans Rubió P; Garrido Morales P; Salleras Sanmartí L
    Rev Esp Salud Publica; 1995; 69(5):409-17. PubMed ID: 8564860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness.
    Fedson DS
    Semin Respir Infect; 1993 Dec; 8(4):285-93. PubMed ID: 7938925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
    Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
    Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
    Silfverdal SA; Berg S; Hemlin C; Jokinen I
    Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
    Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
    Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium].
    De Graeve D; Verhaegen J; Ament A; Baltussen R
    Acta Clin Belg; 2000; 55(5):257-65. PubMed ID: 11109640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
    Marchetti M; Colombo GL
    Vaccine; 2005 Aug; 23(37):4565-76. PubMed ID: 15992969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
    Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
    Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness.
    Simberkoff MS
    Semin Respir Infect; 1993 Dec; 8(4):294-9. PubMed ID: 7938926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost benefits of targeting the pneumococcal vaccination program to the elderly population in Taiwan.
    Chen YH; Yang GY; Loh CH; Liou SH; Su WL; Lin SH; Chou CC
    Am J Infect Control; 2006 Nov; 34(9):597-9. PubMed ID: 17097456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of pneumococcal conjugate vaccination in Finland.
    Salo H; Sintonen H; Nuorti JP; Linna M; Nohynek H; Verho J; Kilpi T
    Scand J Infect Dis; 2005; 37(11-12):821-32. PubMed ID: 16308215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.